None listed
Conditions
Interventions
treatment group:Longmu Moisturizing Formula
Sponsors
Xiyuan Hospital, China Academy of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
19 Years to 50 Years
Inclusion criteria
Inclusion criteria: (1) According to the Chinese Guidelines for the Diagnosis and Treatment of Atopic Dermatitis (2020 Edition) for adults with AD diagnosis, they meet the diagnosis of AD Break; Diagnostic criteria for AD in Chinese adolescents/adults: Persistent or recurrent symmetrical eczema (dermatitis) for more than 6 months At least one of the following: Personal history of allergic rhinitis and/or allergic asthma and/or allergic conjunctivitis Eczema/AD and/or allergic rhinitis and/or allergic wheezing in a first, second, or third-degree relative Family history of asthma and/or allergic conjunctivitis Elevated serum total IgE levels and/or positive allergen-specific IgE and/or eosinophilia many Exclusions: Hypereosinophilic Syndrome, Wiscott-Aldrich Syndrome, Netherton Syndrome, HyperIgE syndrome, Sezary disease, and other diseases (2) Those who meet the above TCM syndrome differentiation and typing criteria; (3) 12 years old= age = 60 years old, male or female; (4) Good compliance, able to comply with the requirements of clinical trials, and comply with medication regulations; (5) The subject or guardian has signed the informed consent form; (6) Blood, urine, and stool routine before treatment, and liver and kidney function tests are within the normal range.
Exclusion criteria
Exclusion criteria: (1) Known allergy to any component of the test drug; (2) Patients who have received systemic glucocorticoid therapy within 2 weeks before the trial or are suspected to be able to affect the specific effect Phototherapy (e.g., UVB, PUVA) or systemic therapy (immunosuppressants, cell growth) for allergic dermatitis inhibitors); (3) Patients who are immunosuppressed (such as lymphoma) or have a history of malignant disease concomitant to any interference with the test results Skin disease assessed; (4) Patients refuse to sign the informed consent form, or those who are estimated to have poor compliance and poor follow-up possibility; (5) Pregnant or lactating women; (6) Other cases that did not meet the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SCORAD scale difference; | — |
Secondary
| Measure | Time frame |
|---|---|
| NRS score;DLQI score; | — |
Countries
China
Contacts
Public ContactYanli Song
Xiyuan Hospital, China Academy of Traditional Chinese Medicine
Outcome results
None listed